Patent Issued for Levodopa dosing regimen (USPTO 12109185).

A patent has been issued for a levodopa dosing regimen by Amneal Pharmaceuticals LLC, aiming to address issues faced by Parkinson's disease patients with levodopa therapy. The patent outlines a dosing regimen that allows for twice or thrice daily dosing of an oral controlled release levodopa composition, providing steady plasma concentrations with minimal fluctuations. The invention seeks to reduce "Off" time and increase "On" and "Good On" time for patients, particularly when dosed every 6 to 12 hours, offering a potential solution to challenges in levodopa treatment for Parkinson's disease. [Extracted from the article]